Time-to-onset analysis of NAEs associated with GLP-1 RAs The median time-to-onset of NAEs for all GLP-1 RAs was 31 days (interquartile range [IQR] 7123), with 46.25% occurring within the first 30 days of treatment initiation (Table S6, Figure S2)
Antimicrobial resistance is a concern, as some peptides impact bacterial populations in unknown ways
Specific lifestyle changes can help individuals stay healthy and keep the weight off: Dose Tapering While patients can stop taking GLP-1s without serious side effects, it is critical to wean off the medication rather than stop taking it suddenly
Also, it decreases the likelihood of scar tissue forming
Aim for a palm-sized portion at each meal
Furthermore, plant virus nanoparticles are stable under gastrointestinal conditions 92 and orally bioavailable 93 , therefore opening the door for global distribution and oral vaccination